Interestingly, this study suggests that circulating FABP4 could be valuable for clinical monitoring of thalassemia-associated metaflammation and cardiometabolic comorbidities, potentially preventing future complications and optimizing iron-chelation therapy. This evidence concerns the gene FABP4 and thalassemia.